NASDAQ : NKTR
Nektar Therapeutics — Key statistics
Healthcare · Biotechnology · United States
Last price 39.18 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.34B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.33B |
| Enterprise Value | 778.73M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 34.14M |
| Shares Outstanding | 34.14M |
| Shares Change (YoY) | +73.25% |
| Shares Change (QoQ) | +33.63% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 89.49% |
| Float | 28.28M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.31 |
| Forward PS | 32.18 |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 14.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.42 |
| Quick Ratio | 9.71 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.22 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -35.75% |
| Return on Assets (ROA) | -12.54% |
| Return on Invested Capital (ROIC) | -51.66% |
| Return on Capital Employed (ROCE) | -12.76% |
| Weighted Average Cost of Capital (WACC) | 11.88% |
| Revenue Per Employee | $866,492 |
| Profits Per Employee | -$2.49M |
| Employee Count | 63 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 64,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.27 |
| 52-Week Price Change | -34.81% |
| 50-Day Moving Average | 55.69 |
| 200-Day Moving Average | 65.01 |
| Relative Strength Index (RSI) | 34.73 |
| Average Volume (20 Days) | 1,029,151 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.00M |
| Short Previous Month | 6.97M |
| Short % of Shares Out | 20.50% |
| Short % of Float | 24.74% |
| Short Ratio (days to cover) | 3.62 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 54.59M |
| Gross Profit | 54.59M |
| Operating Income | -130.64M |
| Pretax Income | -157.06M |
| Net Income | -157.13M |
| EBITDA | -129.95M |
| EBIT | -130.64M |
| Loss Per Share | -$6.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 684.34M |
| Total Debt | 135.93M |
| Net Cash | 548.41M |
| Net Cash Per Share | $16.06 |
| Equity (Book Value) | 903.12M |
| Book Value Per Share | 26.46 |
| Working Capital | 668.42M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -233.79M |
| Capital Expenditures | -941,000 |
| Depreciation & Amortization | 693,000 |
| Net Borrowing | 287.55M |
| Free Cash Flow | -234.73M |
| FCF Per Share | -$6.87 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -239.32% |
| Pretax Margin | -287.72% |
| Profit Margin | -287.84% |
| EBITDA Margin | -238.05% |
| EBIT Margin | -239.32% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -73.25% |
| Shareholder Yield | -73.25% |
| Earnings Yield | -16.64% |
| FCF Yield | -17.69% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $133.08 |
| Price Target Difference | 242.37% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | -13.50% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 9, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.21 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |